Nivolumab, Docetaxel, and ADT Triplet Confers Antitumor Activity in mCRPC Regardless of Prior NAT Use
Karim Fizazi, MD, PhD, presents final analysis results from arm B of the phase 2 CheckMate 9KD trial.
Karim Fizazi, MD, PhD, presents final analysis results from arm B of the phase 2 CheckMate 9KD trial.
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
Investigators of this real-world analysis studied survival trends among patients with muscle-invasive bladder cancer (MIBC) and patients with metastatic urothelial carcinoma (UC).
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Kessel et al present the final efficacy and safety results from a phase 2 study of radium-223 plus enzalutamide vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer (mCRPC).
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Real-world data show that a combination of a first-generation anti-androgen drug and androgen deprivation therapy is no better than ADT alone in improving outcomes among men with metastatic castration-sensitive prostate cancer.
Investigators say they believe their study is the first to show a link between circulating tumor cell counts and progression-free and overall survival in men with metastatic hormone-sensitive prostate cancer.